Spelling suggestions: "subject:"activin"" "subject:"activins""
11 |
Activin in early vertebrate and human developmentBartlett, Simon Robert January 1996 (has links)
No description available.
|
12 |
Modulation of growth factors and cell cycle regulatory molecules in experimental cardiomyopathyMahmoudabady, Maryam 22 September 2009 (has links)
Background: Different types of cardiomyopathies are associated with variable hypertrophic response.
A number of growth factors are thought to play a role in pathologic cardiac remodeling.
Aims: We compared the modulation of the TGF-ƓÒ superfamily and IGF-1 signaling pathways and their target genes, the cell cycle regulatory proteins in tachycardia-induced dilated cardiomyopathy, a model with no detectable hypertrophy and in ischemic cardiomyopathy, a model with a marked hypertrophic reaction.
Methods: In the first study, endomyocardial biopsies were obtained weekly in 15 dogs, during the development of tachycardiomyopaty. Genes involved in the myostatin-TGF-ƓÒ-Activin-A/Smad signaling pathway, p21 and cyclin D were quantified and correlated to echocardiographic measures of hypertrophy. In the second study, myocardial tissue samples were obtained in 8 dogs with a healed myocardial infarction, in 8 dogs with heart failure induced by overpacing and in 7 healthy dogs. We measured gene expression of IGF-1, its receptor (IGF-1R) and cyclins A, B, D1, D2, D3 and E and correlated them to the level of hypertrophy.
Results: Tachycardiomyopathy was characterized by chambers dilation with no identifiable hypertrophy. Ischemic cardiomyopathy was characterized by eccentric hypertrophy. In tachycardiomyopathy, Activin-A mRNA was 4-fold higher than at baseline. Smad7 was overexpressed in severe heart failure; p21, a direct target gene of the Smad pathway was upregulated 8-fold and cyclin D1 was down-regulated. In that model, IGF-1 was overexpressed but neither IGF-1R nor any of the cyclins studied.
In ischemic cardiomyopathy, IGF-1, IGF-R, and cyclins B, D1, D3 and E gene expression were upregulated.
In tachycardiomyopathy, Activin-A and p21 were inversely correlated to the thickness of the interventricular septum. In normal dogs and in the both models of cardiomyopathy, IGF-1R was correlated to the thickness of the interventricular septum and to cyclins.
Conclusions: Taken together, these results agree with the notion that Activin-A, IGF and cyclins are involved in the modulation of hypertrophic response observed in cardiomyopathies.
|
13 |
The role of activin system during gonad growth in black porgy (Acanthopagrus schlegeli): the interplay in bisexual gonad mediate by activin system through brain-pituitary-gonad axisChung, Yi-jou 25 July 2011 (has links)
Inhibin and activin are disulphide-linked dimeric proteins that belong to the transforming growth factor superfamily. Inhibin and activin are identified that they have ability to modulate the secretion of follicle-stimulating hormone, FSH, from pituitary. Activin can stimulate FSH secretion, on the other hand, inhibin can inhibit
FSH production. According to many researches, inhibin and activin play an important
roles in regulation of reproduction. Black porgy (Acanthopagrus schlegeli) is belong
to protandry.that has a complex regulation in sex differentiation and development. The
male differentiation in black porgy started at fourth month, and the testis become
mature when the spawing season coming.in the first two year in black porgy, they are
differentiate to functional males, and some of them will change to females in the third
year. The objectives were to study the possible roles of inhibin¡Bactivin subunits and
their receptors in sex differentiation and sex change in black porgy. The gene
expression of activin system increase during the period of ovarian development. The
expression of activin receptors in ovarian tissue are higher than in testis tissue in the
testis-excision experiment. The expression of inhbab ¡Bacvr1and acvr2b after
testis-excision are higher than in control in black porgy forebrain. The expression of
inhbaa increase at four to five months after hatching in 0+-yr old black porgy, and the
expression of inhbb and receptors decrease at the same time. According to these
results, activin system may involve in the ovarian development and mature, and play
important roles in testis differentiation and development in black porgy. Furthermore,
activin system have sex dimorphisms in forebrain in black porgy.
|
14 |
The expression of the activin phenotype in the wound healing of diabetic ratsTsai, Chiung-mei 31 July 2005 (has links)
Activin is a dimeric protein of inhibin beta subunit, which is abundantly stored in normal bone matrix, presumably produced by osteoblasts in the process of normal bone formation. The expression of activins was examined in the wound healing of diabetic rats. In this study,insulin-dependent diabetes mellitus was induced in a group of mature Sprague-Dawley rats by injecting streptozotocin. Control animals were injected with citrate buffer only. After 3 weeks,all of rats underwent extraction of the right maxillary molars teeth after anesthesia. Rats were killed at varying intervals and the maxilla and calvaria were recovered in continuity. Tissue sections were stained with hematoxylin-eosin as well as immunohistochemical gent. Hematoxylin-eosin analyses showed that at 7 days after tooth extraction in the control and insulin-streptozotocin-treated rats there were, thick collagen fibers which formed a pretrabecular the scaffold dictated the direction of the forming trabeculae. However,the collagen fibers in the diabetic socket were thin and scanty, and only formed a narrow layer in the apical part of the socket. These histologic observations suggest that in uncontrolled, insulin-dependent diabetes, the formation of the collagenous framework in the tooth extraction socket is inhibited, resulting in delayed healing.The immunohistochemical analyses showed that at 7 days after tooth extraction in both control and insulin-streptozotocin-treated rats, osteoblasts were increased in extra-alveolar bone formation.Our findings also suggested that activin was actively involve in bone modeling during osteogenesis. These findings suggest that activin may play important role in the regulation of bone formation and it may be useful in the future for the wound healing in diabetic patients.
|
15 |
Functional studies of pituitary activin/follistatin system in grass carpFung, Sai-kit, 馮世傑 January 2010 (has links)
published_or_final_version / Biological Sciences / Doctoral / Doctor of Philosophy
|
16 |
The Roles of Activin A and B in Liver Inflammation and FibrosisMatthew Joseph Hamang (6640730) 15 May 2019 (has links)
<p>Liver fibrosis is the result of
different types of chronic liver diseases, such as cholestatic liver disease and nonalcoholic steatohepatitis, among others.
Fibrosis, if left unchecked, may progress to the point of cirrhosis –
permanently affecting liver function detrimentally and potentially leading to
development of hepatocellular carcinoma.
Inflammatory response following tissue injury is vital for the
initiation of fibrosis; chronic inflammation results in abnormal tissue healing
and promotes a pro-fibrogenic response.</p>
<p>Activins are cytokines that
have been identified as members of the TGFβ superfamily of growth and differentiation factors. Activin A and B, in particular, have been
identified as having roles in the pathophysiology of liver disease, but have
not been investigated thoroughly. We
treated mice with concanavalin A, a potent T-cell mitogen with liver
specificity when administered intravenously, and characterized the resulting
response to liver injury and how activin A and B are modulated during this
acute inflammatory phase. We showed that
activin B is highly increased in circulation following inflammation, as well as
locally in the liver as well as the spleen.
We then neutralized activin A and B via neutralizing antibodies in our
concanavalin A-induced liver injury model to determine if inhibition of these
ligands may confer protective effects during the acute inflammatory response in
liver. Neutralization of either activin
A or activin B protected hepatocytes, improved liver function, and
significantly reduced circulating cytokines following concanavalin A
administration. Finally, we determined
whether inhibition of activin A or B might prevent or reverse the development
of liver fibrosis after disease has been established. We induced liver fibrosis in mice via the
hepatotoxin carbon tetrachloride, and then treated with neutralizing antibodies
while still maintaining carbon tetrachloride administration. Neutralization of activin A and B markedly
reduced liver fibrosis, protected hepatocytes, and improved liver
function. Our findings implicate both
activin A and B as major players in the acute inflammatory response to liver
injury, as well as during chronic injury and fibrogenesis, and demonstrate the
therapeutic potential of targeting these ligands for the treatment of fibrosis
in chronic liver diseases.</p>
|
17 |
TGF-beta signaling in an in vivo model of NASHCulver, Alexander January 2016 (has links)
Indiana University-Purdue University Indianapolis (IUPUI) / A burgeoning area of focus within liver disease research is centered on the concomitant muscle atrophy present in end stage liver disease patients which shows a correlation to severity of hepatic fibrosis and transplant survival outcomes. Of particular interest, nonalcoholic steatohepatitis (NASH) is a form of liver disease that is characterized as the hepatic manifestation of metabolic syndrome. If left untreated, the disease can progress to the state of cirrhosis and hepatocellular carcinoma requiring transplant. Concordant with increasing global prevalence of obesity, NASH is projected to become the leading cause for liver transplants by 2020. Due to a lack of therapeutic options, these patients represent a large unmet medical need in the western world. A major hurdle to therapeutic research is the lack of a quick, reproducible, and cost effective in vivo model that recapitulates the plethora of pathologies and their molecular underpinnings manifested by this disorder. Our studies attempted to validate and expand upon a two-hit model of NASH, which incorporated both the integral comorbidities associated with metabolic challenges of obesity along with liver injury. The two-hit model manifests not only the hepatic morphohistological characteristics of the disease, but also incorporates the obligatory muscle atrophy. To further elaborate on the potential direct link between liver and skeletal muscle and remove any confounding issues associated with the model, in vitro administration of hepatotoxins representing various pathologies associated with liver disease, were used to recapitulate the liver-muscle endocrine signaling that exists in vivo. Our data shows that a variety of hepatoxins can elicit hepatocellular damage which releases factors that inhibits myotube size in vitro. The two hit model also preserves many of conserved molecular underpinnings observed in clinical hepatic fibrosis. Of particular interest, the TGFβ superfamily has been demonstrated to play an important regulatory role in the progression of fibrosis in NASH patients. TGFβ, Activin A, and Follistatin are members of the highly conserved family that are increased in NASH patients. Furthermore, these proteins have a well-studied role in muscle health, regeneration, and mass that has been hypothesized to be conserved between liver and muscle tissues. Surprisingly, novel expression of the myokine and negative regulator of muscle mass Gdf8 (myostatin) was increased in our in vivo model as well. Our studies focused on the molecular interactions of these TGFβ superfamily members and their role on liver disease progression. Through specific inhibition of these proteins (Activin A and Gdf8), we demonstrated that they appear to play key individual roles in the progression of the concomitant muscle atrophy observed in NASH patients. Interestingly, superior efficacy was gained with the treatment of a pan inhibitor of these proteins (Activin A, B, Gdf8 etc.) via a soluble decoy receptor (ActRIIB-Fc), suggesting an additional unaccounted for ligand. Activin B, was found to be increased in two separate in vivo models of liver fibrosis (two-hit model and BDL), has been implicated in regulating muscle mass. Our data suggest a pivotal role for several members of the TGFβ superfamily in NASH associated muscle atrophy. Therapies designed to treat liver fibrosis and the resultant decrements in muscle mass and force must account for these agents which will require pan inhibition of TGFβ superfamily ligands that signal through the ActRIIB receptor.
|
18 |
The Role of Activin B in Skeletal Muscle Injury and RegenerationYaden, Melissa A. 12 1900 (has links)
Indiana University-Purdue University Indianapolis (IUPUI) / Acute skeletal muscle injury leads to increases in activin B levels and when selectively neutralized with a monoclonal antibody, there is augmented skeletal muscle repair.
|
19 |
Structural and Biochemical Insights into Myostatin RegulationCash, Jennifer N. 23 September 2011 (has links)
No description available.
|
20 |
Molecular Regulation of Follistatin by Caveolin-1 in Glomerular Mesangial Cells and its Therapeutic Potential in Chronic Kidney Disease / The Therapeutic Role of Follistatin in Chronic Kidney DiseaseMehta, Neel January 2019 (has links)
Chronic kidney disease (CKD) is a major cause of morbidity and mortality, affecting more than 10% of the world’s population. CKD is associated with excessive renal fibrosis, which leads to declining kidney function and eventual kidney failure. In CKD, glomerular mesangial cells (MC), resident fibroblasts and tubular epithelial cells undergo phenotypic activation and transition in response to profibrotic and proinflammatory cytokines such as transforming growth factor β1 (TGFβ1). These activated renal cells excessively produce extracellular matrix (ECM) proteins that replace functional renal tissue and lead to renal fibrosis. Caveolae are small omega-shaped invaginations of the plasma membrane that mediate signaling transduction events. Formation of caveolae require the protein caveolin-1 (cav-1). We have previously shown that the ability of MC to produce matrix proteins is dependent on cav-1 expression. Unfortunately, clinically targeting cav-1 within the kidneys, specifically within MC, is technically challenging and as of yet unfeasible. Thus, to better understand how cav-1 deletion is protective, we carried out a microarray screen comparing cav-1 wild-type (WT) and knockout (KO) MC. Here, we discovered significant up-regulation of a TGFβ superfamily inhibitory protein, follistatin (FST). FST specifically targets and neutralizes activin A (ActA) but not TGFβ1. TGFβ1 and ActA both belong to the TGFβ superfamily of cytokines and growth factors. While TGFβ1 itself is a known key mediator of renal fibrosis, therapies aimed at directly inhibiting TGFβ1 in kidney diseases have not been successful due to opposing profibrotic and anti-inflammatory effects. ActA has been shown to act as a strong profibrotic and proinflammatory agent in various organs, including the lungs and liver. We along with others have observed elevated levels of ActA within the kidneys and serum of mice and humans with CKD. Functionally, ActA has been shown to contribute to ECM production in the kidneys. Hence, we hypothesized that ActA inhibition through FST could prove beneficial in CKD. In this thesis, our first study elucidated a novel molecular pathway by which cav-1 regulates expression of the FST in MC. Our results indicate that FST is negatively regulated by cav-1 through a PI3K/PKC zeta/Sp1 transcriptional pathway. Our second study expands on these findings and tests whether exogenous FST administration protects against the progression of CKD in a surgical mouse model of CKD. Here, we discovered that FST acts as a reactive oxygen species (ROS) scavenger and that exogenous administration of FST protects against the development of CKD through the inhibition of renal fibrosis and oxidative stress. Lastly, our third study determined whether microRNAs (miRNAs) are implicated in post-transcriptionally regulating FST through cav-1 and whether these FST-targeting miRNAs can be utilized therapeutically to protect against the development and progression of CKD. Here, we determined that a FST-targeting miRNA, microRNA299a-5p, is significantly downregulated in cav-1 deficient MC, upregulated in vivo in a mouse model of CKD and that its inhibition, in vitro and in vivo protects against the accumulation of ECM proteins and renal fibrosis. These studies collectively suggest that FST is an effective therapeutic option for the management of CKD. / Thesis / Doctor of Philosophy (PhD) / Chronic kidney disease results from excessive fibrosis (scarring) within the kidneys. The goal of this thesis is to understand the molecular mechanisms involving the regulation of an antifibrotic protein, follistatin, in glomerular mesangial cells and to identify its therapeutic potential in chronic kidney disease. This thesis has identified that follistatin, an endogenous inhibitor of the profibrotic cytokine activin A, is regulated transcriptionally by Sp1 and post-transcriptionally by microRNA299a-5p. Furthermore, this thesis has demonstrated that exogenous recombinant follistatin administration protects against the progression of chronic kidney disease and that microRNA299a-5p targeting may be an alternative approach to block renal fibrosis. These studies collectively show that follistatin is an effective treatment for the management of chronic kidney disease.
|
Page generated in 0.0446 seconds